Loading...
Drug Pricing Controls And Approval Delays Will Curb Viability
AnalystLowTarget's Fair Value
US$1.00
38.0% overvalued intrinsic discount04 Sep
US$1.38
1Y
-67.3%7D
-2.1%1Y
-67.3%7D
-2.1%You can edit this narrative until Aug 22 10:33 PM. Then, changes will post as Updates.